As of 2026-09-25, the EV/EBITDA ratio of Ocular Therapeutix Inc (OCUL) is -5.27. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OCUL's latest enterprise value is 1,624.34 mil USD. OCUL's TTM EBITDA according to its financial statements is -308.46 mil USD. Dividing these 2 quantities gives us the above OCUL EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.4x - 11.1x | 8.7x |
| Forward P/E multiples | 11.4x - 16.0x | 14.1x |
| Fair Price | (13.71) - (13.21) | (13.66) |
| Upside | -239.7% - -234.5% | -239.1% |
| Date | EV/EBITDA |
| 2026-09-24 | -5.27 |
| 2026-09-23 | -5.39 |
| 2026-09-22 | -5.75 |
| 2026-09-21 | -5.39 |
| 2026-09-18 | -5.39 |
| 2026-09-17 | -5.49 |
| 2026-09-16 | -5.30 |
| 2026-09-15 | -5.53 |
| 2026-09-14 | -5.90 |
| 2026-09-11 | -5.74 |
| 2026-09-10 | -5.83 |
| 2026-09-09 | -6.44 |
| 2026-09-08 | -6.37 |
| 2026-09-04 | -5.85 |
| 2026-09-03 | -5.85 |
| 2026-09-02 | -6.03 |
| 2026-09-01 | -5.80 |
| 2026-08-31 | -5.74 |
| 2026-08-28 | -5.65 |
| 2026-08-27 | -5.98 |
| 2026-08-26 | -5.94 |
| 2026-08-25 | -6.02 |
| 2026-08-24 | -5.95 |
| 2026-08-21 | -6.16 |
| 2026-08-20 | -6.17 |
| 2026-08-19 | -6.62 |
| 2026-08-18 | -6.11 |
| 2026-08-17 | -5.86 |
| 2026-08-14 | -5.42 |
| 2026-08-13 | -5.46 |
| 2026-08-12 | -5.56 |
| 2026-08-11 | -5.22 |
| 2026-08-10 | -4.85 |
| 2026-08-07 | -4.82 |
| 2026-08-06 | -4.50 |
| 2026-08-05 | -4.33 |
| 2026-08-04 | -4.39 |
| 2026-08-03 | -4.26 |
| 2026-07-31 | -4.09 |
| 2026-07-30 | -4.31 |
| 2026-07-29 | -4.23 |
| 2026-07-28 | -4.29 |
| 2026-07-27 | -4.43 |
| 2026-07-24 | -4.33 |
| 2026-07-23 | -4.41 |
| 2026-07-22 | -4.39 |
| 2026-07-21 | -4.63 |
| 2026-07-20 | -4.48 |
| 2026-07-17 | -4.66 |
| 2026-07-16 | -4.80 |